|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-1-1
|
|
pubmed:abstractText |
beta-Lapachone (ARQ 501, a formulation of beta-lapachone complexed with hydroxypropyl-beta-cyclodextrin) is a novel anticancer agent with selectivity against prostate cancer cells overexpressing the NAD(P)H:quinone oxidoreductase-1 enzyme. Lack of solubility and an efficient drug delivery strategy limits this compound in clinical applications. In this study, we aimed to develop beta-lapachone-containing polymer implants (millirods) for direct implantation into prostate tumors to test the hypothesis that the combination of a tumor-specific anticancer agent with site-specific release of the agent will lead to significant antitumor efficacy.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-10077223,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-10681517,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-11125352,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-11193903,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-11279125,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-11288079,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-11340899,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-11412042,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-12074689,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-12787712,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-12820771,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-12918123,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-12932647,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-14503938,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-14520404,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-14566792,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-14620518,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-15336979,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-15662131,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-15837761,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-15937647,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-16237291,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-16310371,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-16482400,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-16883563,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-16920718,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-17120197,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-17120205,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-17169648,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-17237035,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-17459271,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-17609380,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-17615529,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-17907765,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-17938702,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-7641180,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19118040-9516435
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
131-9
|
|
pubmed:dateRevised |
2011-9-26
|
|
pubmed:meshHeading |
pubmed-meshheading:19118040-Animals,
pubmed-meshheading:19118040-Antineoplastic Agents,
pubmed-meshheading:19118040-Cell Line, Tumor,
pubmed-meshheading:19118040-Drug Carriers,
pubmed-meshheading:19118040-Drug Implants,
pubmed-meshheading:19118040-Humans,
pubmed-meshheading:19118040-Male,
pubmed-meshheading:19118040-Mice,
pubmed-meshheading:19118040-Mice, Nude,
pubmed-meshheading:19118040-Naphthoquinones,
pubmed-meshheading:19118040-Polymers,
pubmed-meshheading:19118040-Prostatic Neoplasms,
pubmed-meshheading:19118040-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy.
|
|
pubmed:affiliation |
Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|
